Current status of cytokine-induced killer cells and combination regimens in breast cancer [PDF]
Frontiers in ImmunologyBreast cancer remains a significant health challenge worldwide, with substantial efforts aimed at understanding its pathogenesis, biological characteristics, and clinical triggers.
Yuancong Jiang +3 more
doaj +6 more sources
Cytokine-induced killer cells: new insights for therapy of hematologic malignancies [PDF]
Stem Cell Research & TherapyBackground Cytokine-induced killer (CIK) cells are a novel subgroup of immune effectors, classified as one of the modified T cell-mediated arms for immunotherapy.
Faezeh Ghanbari Sevari +4 more
doaj +4 more sources
Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer [PDF]
Cell Communication and Signaling, 2022 Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors.
Farimah Fayyaz +2 more
doaj +4 more sources
Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer [PDF]
BMC Cancer, 2020 Background This study aimed to investigate the efficacy and safety of cytokine-induced killer (CIK)/dendritic cell combined with CIK (DC–CIK) cell therapy in advanced gastrointestinal cancer (GIC).
Hansong Du, Jia Yang, Ying Zhang
doaj +3 more sources
An Exploratory in vitro Study of Cytotoxicity and Cytokine Profiling of Cytokine-Induced Killer (CIK) Cells Against HCT-15 Colorectal Cancer (CRC) Cells [PDF]
ImmunoTargets and TherapySze-Piaw Chin,1,2 Natasha Najwa Nor Arfuzir,1 Vivian Wai-Ping Kong,3 Soon-Keng Cheong1,2 1Department of Research and Development, Cytopeutics Sdn Bhd, Cyberjaya, Selangor, Malaysia; 2M.
Chin SP +3 more
doaj +2 more sources
How can Cytokine-induced killer cells overcome CAR-T cell limits [PDF]
Frontiers in Immunology, 2023 The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy (ACT).
Elisa Cappuzzello +7 more
doaj +2 more sources
Efficacy of modified dendritic cell–cytokine-induced killer cells loaded with tumour stem cell membrane microparticle therapy in the treatment of relapsed or refractory T- and NK-cell lymphoid proliferations and lymphomas: a report of three cases [PDF]
Annals of HematologyThe prognosis of relapsed or refractory T-cell and NK-cell lymphoid proliferations and lymphomas (R/R T/NK-LPD/LYM) remains poor. Modified dendritic cell–cytokine-induced killer (DC–CIK) cells loaded with tumour stem cell (TSC) membrane microparticles ...
Ao Wang +5 more
doaj +2 more sources
Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab [PDF]
AntibodiesStrategies to increase the anti-tumor efficacy of cytokine-induced killer cells (CIKs) include genetic modification with chimeric antigen receptors (CARs) or the addition of soluble T-cell engaging bispecific antibodies (BsAbs).
Silvia Zaninelli +10 more
doaj +2 more sources
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma [PDF]
Frontiers in ImmunologyMunch Christian +2 more
exaly +2 more sources
30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
Journal of Experimental & Clinical Cancer Research, 2021 Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be
Amit Sharma, Ingo G. H. Schmidt-Wolf
doaj +1 more source